DR2313 | PARP inhibitor manufacturers
- DR2313
-
- $29.00
-
2026-07-27
- CAS:284028-90-6
- Purity: 99.84%
- Supply Ability: 10g
|
| | DR2313 | PARP inhibitor Basic information |
| Product Name: | DR2313 | PARP inhibitor | | Synonyms: | 1,5,7,8-TETRAHYDRO-2-METHYL-4H-THIOPYRANO[4,3-D]PYRIMIDIN-4-ONE;DR 2313;7,8-Dihydro-2-methyl-1H-thiopyrano[4,3-d]pyrimidin-4(5H)-one;3,5,7,8-Tetrahydro-2-methyl-4H-thiopyrano[4,3-d]pyrimidin-4-one;4H-Thiopyrano[4,3-d]pyriMidin-4-one,3,5,7,8-tetrahydro-2;4H-THIOPYRANO[4,3-D]PYRIMIDIN-4-ONE,3,5,7,8-TETRAHYDRO-2-METHYL-;SC-202756;2-Methyl-1-sulfanyl-1H,4H,5H,7H,8H-pyrano[4,3-d]pyriMidin-4-one | | CAS: | 284028-90-6 | | MF: | C8H10N2OS | | MW: | 182.24 | | EINECS: | 200-589-5 | | Product Categories: | | | Mol File: | 284028-90-6.mol |  |
| | DR2313 | PARP inhibitor Chemical Properties |
| Boiling point | 349.3±52.0 °C(Predicted) | | density | 1.46±0.1 g/cm3(Predicted) | | storage temp. | Sealed in dry,2-8°C | | solubility | H2O: >2mg/mL (warmed) | | form | powder | | pka | 1.54±0.20(Predicted) | | color | white to beige | | Water Solubility | H2O: >2mg/mL (warmed) | | InChI | 1S/C8H10N2OS/c1-5-9-7-2-3-12-4-6(7)8(11)10-5/h2-4H2,1H3,(H,9,10,11) | | InChIKey | HRYKZAKEAVZGJD-UHFFFAOYSA-N | | SMILES | CC1=NC(=O)C2=C(CCSC2)N1 |
| WGK Germany | 3 | | Storage Class | 11 - Combustible Solids |
| | DR2313 | PARP inhibitor Usage And Synthesis |
| Uses | DR2313 is a potent, selective, competitive and brain-penetrant inhibitor of poly(ADP-ribose) polymerase (PARP), with IC50s of 0.20 μM and 0.24 μM for PARP-1 and PARP-2, respectively. DR2313 exhibits neuroprotective effects on ischemic injuries in vitro and in vivo[1][2]. | | Biological Activity | Potent, competitive inhibitor of poly(ADP-ribose) polymerase (PARP) (IC 50 values are 0.20 and 0.24 μ M for PARP-1 and PARP-2 respectively). Neuroprotective; reduces neuronal cell death in models of cerebral ischemia in vivo and in vitro . Brain penetrant. | | in vivo | DR2313 (3-10 mg/kg i.v. bolus or infusion for 6 h) significantly reduces the cortical infarct volume in both permanent and transient focal ischemia models in rats[1].
| Animal Model: | Male Wistar rats (220-300 g) with permanent MCA occlusions (pMCAos) and transient MCA occlusions (tMCAos)[1] | | Dosage: | 3, 10 mg/kg | | Administration: | I.v. bolus and i.v. infusion for 6 h beginning 5 min before the onset of ischemia | | Result: | Reduced the infarct volume in a dose-dependent manner in pMCAo and tMCAo model. |
| | IC 50 | PARP-1: 0.20 μM (IC50); PARP-2: 0.24 μM (IC50) | | References | [1] Nakajima H, et, al. A newly synthesized poly(ADP-ribose) polymerase inhibitor, DR2313 [2-methyl-3,5,7,8-tetrahydrothiopyrano[4,3-d]-pyrimidine-4-one]: pharmacological profiles, neuroprotective effects, and therapeutic time window in cerebral ischemia in rats. J Pharmacol Exp Ther. 2005 Feb;312(2):472-81. DOI:10.1124/jpet.104.075465
[2] Xu Z, et, al. Endonuclease G does not play an obligatory role in poly(ADP-ribose) polymerase-dependent cell death after transient focal cerebral ischemia. Am J Physiol Regul Integr Comp Physiol. 2010 Jul;299(1):R215-21. DOI:10.1152/ajpregu.00747.2009 |
| | DR2313 | PARP inhibitor Preparation Products And Raw materials |
|